Sac-TMT is a novel human TROP2 ADC with proprietary intellectual property, targeting advanced solid tumors
Clinical trials found that 77% of patients went into remission after receiving obe-cel
The trial tested six injectable doses and three oral doses over as long as 36 weeks
Deceased donor kidney transplants are time-critical, and it is uncommon to attempt them robotically
Itvisma is a one-time, fixed-dose therapy designed to tackle the genetic root cause of SMA
The deliveries bring the innovative medicine to communities heavily impacted by HIV just five months after U.S. FDA approval
The therapy -- Ryoncil (remestemcel-L-rknd) -- will be tested in adults with severe steroid-refractory acute graft-versus-host disease
Subscribe To Our Newsletter & Stay Updated